Highlights

• KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.
• Aducanumab (BIIB) produces one of the highest frequencies of amyloid-related edema but also has the most encouraging results in Phase I.
• Crenezumab (Roche) data shows that targeting mid-domain Abeta, there is a tendency to target more soluble species and since benefit in the mildest patients.
• Gantenerumab targeted the N-terminus, similar to bapineuzumab, so it’s unclear whether they should be looking at a higher dose.
• Tau targeted therapies like LMTX (TauRx) and azeliragon (vTV Therapeutics) don’t have to be either or, combinations may be beneficial.
• Amyloid imaging agent reimbursement to identify early AD population will likely change if a disease modifying drug is approved.
• Encenicline Alpha 7 (Forum) and idalopirdine (Lundbeck) 5HT-6 symptomatic therapies will need to be used in conjunction with AchEIs to be relevant.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.